Evaluation of fixed continuous positive airway pressure (CPAP) with C-Flex+ against fixed CPAP
| ISRCTN | ISRCTN04363711 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN04363711 |
| Protocol serial number | EAME09PRSTS02 |
| Sponsor | Philips Respironics (France) |
| Funder | Philips Respironics (France) |
- Submission date
- 07/12/2010
- Registration date
- 13/01/2011
- Last edited
- 13/01/2011
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nervous System Diseases
Plain English summary of protocol
Not provided at time of registration
Contact information
Scientific
Center of Sleep Medicine
Department of Internal Medicine
Charité-Universitätsmedizin Berlin, CCM
Luisenstr. 13
Berlin
10117
Germany
| ingo.fietze@charite.de |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Double blind randomised controlled study |
| Secondary study design | Randomised controlled trial |
| Study type | Participant information sheet |
| Scientific title | Evaluation of fixed continuous positive airway pressure (CPAP) with C-Flex+ against fixed CPAP in patients with obstructive sleep apnoea |
| Study acronym | C-Flex+ |
| Study objectives | Compare the performance of a fixed continuous positive airway pressure (CPAP) device with C-Flex+ (REMstar® Pro) against fixed CPAP in patients with obstructive sleep apnoea (OSA) and validate its event detection capabilities. Primary hypothesis and end-points: 1. Fixed CPAP with C-Flex+ delivered over one night by the REMstar® Pro, to subjects with OSA, will reduce the Apnoea-Hypopnoea Index (AHI) score to a similar level to fixed CPAP delivered by the same device over one night. Secondary hypotheses and end-points: 1. Fixed CPAP with C-Flex+ delivered throughout the night by the REMstar® Pro, to subjects with OSA, will reduce the following variables to a similar level to fixed CPAP delivered by the same device: 1.1. SpO2 - Nocturnal oxygenation 1.1.1. Total time spent less than 90% 1.1.2. Lowest SpO2 during the night 1.1.3. Average SpO2 during the night 1.2. TST - Total sleep time 1.3. SE% Sleep efficiency 1.4. Sleep Architecture: 1.4.1. Min/% Non-REM sleep 1.4.1.1. Min/% N1 1.4.1.2. Min/% N2 1.4.1.3. Min/% N3 1.4.2. Min/% R sleep 1.4.3. Min/% Wake After Sleep Onset (WASO) 1.4.4. Arousals 1.4.4.1. # of arousals/awakenings (all cause) 1.4.4.2. Arousals due to PLMS 1.4.4.3. Arousal Index (AI) 1.4.4.4. Arousals due to Respiratory Disturbance (RDI) 2. Average Pressure Outputs will be lower on C-Flex+ 3. Comfort will be rated as higher when using fixed CPAP with C-Flex+ and patients will prefer it to fixed CPAP 4. The breathing event output from the REMstar Pro will result in a number of events (AHI, flow limitation, RERAs, snore, clear airway apnoeas, obstructed airway apnoeas, hypopnoeas and periodic breathing) that is in diagnostic agreement with those obtained from a full clinical PSG over one night. |
| Ethics approval(s) | Ethikkommision, Ethikausschuss 1 am Campus Charité - Mitte approved on the 11th March 2010 (ref: EA1/036/10) |
| Health condition(s) or problem(s) studied | Obstructive sleep apnoea |
| Intervention | Following the standard education and acclimatisation program of the centre, in which subjects will undergo a daytime CPAP session at a constant pressure of 5 cmH2O using several different interface models so that an appropriate interface can be selected, eligible subjects will complete a CPAP titration study under full PSG conditions. CPAP shall start with a value of 4 cmH2O and be increased in 1cmH2O increments to the point where disordered breathing, including hypopnoeas, RERAs and flow limitations, is eliminated. Respironics' Integrated heated humidifier will be used if needed and set to an initial setting of 2. During the course of the night, this setting can be changed to optimise participant comfort. This study shall be interpreted by the co-investigator to determine the optimal CPAP setting. A successful titration will be defined as an AHI less than 15.0/h under the determined optimal pressure. Subjects in whom CPAP does not adequately treat OSA during the titration will be excluded. Following the CPAP determination study, subjects will be randomly assigned to one night of fixed CPAP with C-Flex+ and one night of fixed CPAP delivered by the REMstar Pro on consecutive nights in the Sleep Laboratory by the PSG technician under full PSG conditions.. These studies should be performed within 14 days of the CPAP determination study. Humidification will be standardised at the level from the CPAP determination study. The same interface will also be used on each occasion. Visual Analogue Scales relating to comfort will be completed immediately upon waking after each therapy night. After the second therapy night a questionnaire asking which device they preferred will also be completed. These assessments will all be administered by the co-investigator at each site. |
| Intervention type | Other |
| Primary outcome measure(s) |
In order to test the primary hypothesis the following PSG variables will be assessed: 1. AHI (total, REM and NREM) - total, obstructive, central, mixed and hypopnoea |
| Key secondary outcome measure(s) |
In order to test the secondary hypotheses the following variables will be assessed: |
| Completion date | 10/01/2012 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Sex | All |
| Target sample size at registration | 85 |
| Key inclusion criteria | 1. AHI greater than 15 confirmed (greater than than 50% obstructive events) by full PSG within last 14 days 2. Age greater than or equal to 21 years of age 3. Able to provide consent 4. Able to follow the instructions given by the investigator regarding using their CPAP device and their participation in this study |
| Key exclusion criteria | 1. Inability to tolerate CPAP during the daytime CPAP session 2. Failure of CPAP to adequately treat OSA during titration (AHI greater than or equal to 15.0/h under the determined optimal pressure) 3. PAP therapy is otherwise medically contraindicated: acute upper respiratory infection, encephalitis, sinusitis or middle ear infection or surgery of the upper airway, nose, sinus, or middle ear within the previous 90 days 4. Untreated, non-OSA sleep disorders, including but not limited to; insomnia, periodic leg movements (PLM)/restless legs syndrome (RLS) 5. Treated insomnia 6. Intake of central relevant drugs, sedatives, or other drugs which impair sleep 7. Previous exposure to positive airways pressure therapy 8. Acute dermatitis or other skin lesions or trauma interfering with the application of a mask 9. Unwilling to participate in the study 10. Participation in another clinical study in the past 4 weeks 11. Shift worker |
| Date of first enrolment | 10/01/2011 |
| Date of final enrolment | 10/01/2012 |
Locations
Countries of recruitment
- Germany
Study participating centre
10117
Germany
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Participant information sheet | Participant information sheet | 11/11/2025 | 11/11/2025 | No | Yes |